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Cl210,1992.-Using the human hepatoma cell line Hep G2, we 
have studied a possible role of protein kinase C (PKC) activity 
for regulation of erythropoietin (EPO) production. During a 
72-h incubation, EPO production by the cells was stimulated 
sevenfold by exposure to low oxygen tension (1%) and threefold 
by exposure to cobaltous chloride (100 PM). The phorbol ester 
phorbol 12-myristate-13 acetate (PMA) led to a concentration- 
dependent inhibition of basal and stimulated EPO formation 
(EDso 10 nM). This decrease of EPO production, which was 
apparent already after 1 h of incubation with PMA, reached its 
maximal effect after 24 h and held on for 72 h. It was paralleled 
by an inhibition of the increase of EPO mRNA levels in 
response to stimulation. A 24-h preincubation of the cells with 
PMA (100 nM) virtually blunted the effect of hypoxia on EPO 
formation. Recovery of EPO synthesis after removal of PMA 
took 48-72 h. The effect of PMA on EPO production was mim- 
icked by phorbol 12,13-dibutyrate (EDso 1 PM) but not by 4~ 
phorbol 12,13-didecanoate. The synthetic diacylglycerol ana- 
logues oleolyl-acetylglycerol and dioctanoylglycerol (2-200 PM) 
also had no effect on either basal or stimulated EPO production. 
Treatment with PMA caused a translocation of the cu-isoen- 
zyme of PKC from the cytosol to the membrane after 1 h and a 
disappearance of the membrane-bound form after 24 h of 
incubation. Staurosporine and 1 -(&isoquinolinylsulfonyl) -2- 
methylpiperazine, two structurally different inhibitors of PKC 
activity, inhibited basal and stimulated EPO production with 
EDs0 values of 9 nM and 50 PM, respectively. Moreover, they 
amplified the inhibitory effect on EPO production exerted by 
PMA. Taken together, our results strongly suggest that PKC 
activity has influence on the regulation of EPO formation in 
Hep G2 cells. 
oxygen sensing; protein kinase C 
THE GLYCOPROTEIN HORMONE erythropoietin (EPO), 
which is considered as the major humoral regulator of 
erythropoiesis, is produced by the kidneys and by the 
liver in response to insufficient oxygen supply and cer- 
tain divalent metals (16). Recent evidence, moreover, 
indicates that the EPO production rate is related to the 
organ levels of EPO mRNA, thus suggesting that 
hepatic and renal EPO production are primarily con- 
trolled by EPO mRNA accumulation (3, 4, 24). The 
elucidation of the intracellular pathways leading to EPO 
mRNA accumulation in response to hypoxia has for long 
been hampered by the fact that neither the liver cells nor 
the kidney cells elaborating EPO could yet be isolated 
and studied in vitro. A major progress on this field was 
achieved by the finding that two human hepatoma cell 
lines (Hep G2, Hep 3B) produce EPO regulated by the 
oxygen tension and by metals similar to the in vivo 
situation (13). The intracellular mechanisms by which 
hypoxia or metals lead to an accumulation of EPO 
mRNA in Hep G2 cells have not yet been elucidated. 
From indirect evidence it was suggested that a heme 
protein functions as oxygen sensor that is essentially 
involved in the signal transduction process (11). 
There is no clear evidence for a role of classic second 
messenger molecules such as cyclic nucleotides in the 
regulation of EPO production in hepatoma cells. It has 
been reported that adenylate cyclase might lead to an 
enhancement of hypoxia-induced EPO formation in 
Hep G2 cells (26). 
A characteristic feature of EPO production is its long- 
lasting stimulation (16). It seems reasonable therefore to 
assume that the signal mechanisms leading to accumu- 
lation of EPO mRNA do not rapidly inactivate but are 
able to mediate continuous stimulation. Such a signal 
transduction pathway that usually mediates longer last- 
ing stimulations in cells is the activation of protein 
kinase C (PKC) (20). A possible role of PKC in the 
regulation of EPO production has to our knowledge not 
yet been thoroughly considered. There is only one report 
saying that phorbol esters do not stimulate EPO forma- 
tion in Hep 3B cells at normoxia during 24 h of incuba- 
tion (11). It appeared reasonable therefore to us to 
address the question about a role of PKC in the regula- 
tion of EPO production utilizing Hep G2 cell cultures. 
For stimulation of PKC activation, we used active 
phorbol esters or synthetic diacylglycerol analogues (20). 
For inhibition of PKC activity, two established PKC 
inhibitors, staurosporine (25) and l-(&isoquinolinylsul- 
fonyl)-2-methylpiperazine (H-7) (14), were used. 
Our results are compatible with the idea that PKC 
activity exerts influence on the regulation of EPO pro- 
duction in Hep G2 cells. 
MATERIALS AND METHODS 
Cell culture. Hep G2 cells were obtained from the American 
Type Culture Collection (Rockville, MD). They were kept in the 
alpha modification of Eagle’s minimal essential medium (cu- 
MEM) supplemented with 10% fetal bovine serum in 25cm2 
flasks, and they were routinely split twice a week (I:20 and 2 
days later 1:lO). Under these conditions the cells only reached 
subconfluency and did not form clumps if cell clumping upon 
seeding was avoided (see below). For the experiments the cells 
were grown in 24-well plates (surface 2 cm2/well) with 300 ~1 of 
culture medium. Cells were seeded at a density of l-l.5 X lo* 
cells/cm2. Seeding of cell clumps was carefully avoided by brief 
and vigorous shaking of the trypsinized cell suspension. Forty- 
eight hours after onset of culture, the medium was renewed, and 
the experiments were started usually for the next 72 h. Each 
experiment was performed in quadruplicate wells. 
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Determination of cellular protein. Cellular protein was taken 
as a measure for cellular mass. It was confirmed that specific 
cellular protein content did not change among the different 
experimental conditions. Specific protein content of Hep G2 
cells was determined to 320 pg protein/lo6 cells. For protein 
determination the culture medium was removed and the cell 
layers were washed twice with 500 ~1 phosphate-buffered saline 
(PBS). Then 500 ~1 PBS supplemented with 0.1% Triton X-100 
were added, and the multiwell plates were shaken at room tem- 
perature for 30 min. Protein content in the cell lysates was 
determined with a commercially available protein assay (Bio- 
Rad) using bovine serum albumin as a standard. 
Production rates of erythropoietin were related to mean cel- 
lular protein (mean protein), which was calculated as the arith- 
metic mean of cellular protein at onset and at end of the 
experiments. 
Determination of EPO. EPO concentrations were deter- 
mined by radioimmunoassay exactly as described (9), with the 
only exception that the standards were dissolved in culture 
medium (a(-MEM plus 10% fetal calf serum). 
Determination of angiotensinogen. Angiotensinogen concen- 
trations were determined by an enzyme-linked immunosorbant 
assay according to Mizrahi et al. (18). 
Ribonuclease (RNase) protection assay for human EPO 
mRNA. The probe used in the RNase protection assay was 
transcribed using SP6 polymerase from a 154-bp fragment 
extending from the Pst I site in exon 3 to the Hind II site in 
exon 4 of the human EPO cDNA. Total RNA was extracted 
from Hep G2 cells using RNAzol (Biogenesis, Bournemouth, 
UK). RNase protection assays were performed under the con- 
ditions described previously (22). In brief, 50 pg of total RNA, 
dissolved in hybridization buffer [80% formamide, 40 mM pip- 
erazine-N,N’-bis(2-ethanesulfonic acid) (PIPES), 400mM 
sodium chloride, 1 mM EDTA, pH 81, were hybridized over- 
night at 60°C after the addition of 0.5-l x lo6 counts/min 
radiolabeled EPO probe. RNase digestion was carried out at 
20°C for 30 min and terminated by adding 60 ~1 of proteinase K 
(1 mg/ml) with 3% sodium dodecyl sulfate (SDS). After phenol- 
chloroform extraction and RNA precipitation, samples were 
redissolved in 80% formamide and electrophoresed on a dena- 
turing 10% polyacrylamide gel. 
Immunodemonstration of PKC subtypes. Hep G2 cells were 
grown in 75-cm2 dishes and incubated with phorbol 12- 
myristate 13-acetate (100 nM) for 0, 1, and 24 h. The culture 
medium was removed and the cell monolayer was washed thrice 
with 10 ml tris(hydroxymethyl)aminomethane (Tris)-buffered 
saline (150 mM NaCl, 70 mM Tris, 5 mM glucose, pH 7.4) 
supplemented with the protease inhibitors leupeptin (10 pg/ml) 
and aprotinin (2 pg/ml). After the last wash, the buffer was 
thoroughly removed, and 1 ml of sonication buffer [20 mM Tris, 
2 mM ethylene glycol-bis(P-aminoethyl ether)-N,N,N’,N’-tet- 
raacetic acid (EGTA), 2 mM EDTA, 6 mM mercaptoethanol, 2 
pg/ml aprotinin, and 10 pg/ml leupeptin] was added. The cells 
were scraped off and sonicated with three 5-s bursts at 70 W. 
The suspension was then centrifuged at 100,000 g for 1 h. Super- 
natants were considered as cytosolic fractions, pellets as partic- 
ulate (membrane) fractions. The pellet was resuspended in the 
sonication buffer supplemented with 1% SDS and heated at 
95°C for 5 min. Protein concentration in cytosolic and mem- 
brane fractions was determined by the Bradford method (6). 
PKC isoenzymes in the cytosolic and membrane fractions (300 
pug protein) were separated by SDS-polyacrylamide gel electro- 
phoresis (17) and then transferred onto nitrocellulose filters. 
After being washed, the filters were incubated with monoclonal 
antibodies against the CY- (Amersham International), ,&, and 
y-isoenzymes of PKC (Seikagaku Kogyo, Tokyo, Japan) exactly 
as described (5). Immunoreactivity was analyzed by autoradiog- 
raphy using 1251-labeled antibodies against mouse y-globulin 
(Amersham International). 
Agents. Phorbol esters, synthetic diacylglycerols, staurospo- 
rine, H-7, aprotinin, and leupeptin were purchased from Sigma 
International. 
Presentation of data. All data are expressed as means ,t SE of 
n experiments. Each experiment represents the mean of qua- 
druplicate wells. 
Statistics. Levels of significance were calculated utilizing 
unpaired t test. P < 0.05 was considered significant. 
RESULTS 
Under standardized conditions, i.e., avoiding of cell 
clumping and seeding of cells at rather low density [cell 
protein at start of experiments: 14.0 t 0.7 (SE) pg/cm2; n 
- - 71, maximal EPO production rates were reproducibly 
obtained during 72-h incubations at 1% oxygen and 100 
PM cobaltous chloride (Fig. 1). EPO production rates at 
20% O2 were 90 t 5 mU EPO/mg mean protein, with 100 
PM cobalt 262 t 35 mU EPO/mg mean protein, and at 
1% O2 662 t 42 mU EPO/mg mean protein. Cell prolif- 
eration was attenuated during 72-h exposure to low oxy- 
gen (mean protein at 1% 02: 30.2 t 0.7 pg/cm2, n = 8; vs. 
mean protein at 20% 02: 34.4 t 1.3 pg/cm2, n = 8) (P < 
0.05) but was not affected by cobalt. 
Incubation of the cells with phorbol 12-myristate 13- 
acetate (PMA) during the 72 h of experiment led to a 
concentration-dependent attenuation of EPO production 
at 20%, 1% O2 and in presence of 100 PM cobalt (Fig. 2). 
The most marked fall of EPO production with PMA was 
seen under 1% 02, where EPO production dropped from 
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Fig. 1. Dependency of 72-h erythropoietin (EPO) production by cul- 
tured Hep G2 cells on extracellular cobalt concentration (top) or oxygen 
tension in the incubation atmosphere (bottom). 
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Fig. 2. Dependency of 72-h EPO production by cultured Hep G2 cells at 
20% 02, 1% 02, and 100 PM cobalt on the concentration of phorbol 
12-myristate-13 acetate (PMA). 
680 to 150 mu. mg mean protein-‘. 72 h-l. The concen- 
tration of PMA required to effectively inhibit EPO pro- 
duction half maximally (ED& was rather constant 
among the different conditions and averaged -10 nM. 
The inhibitory effect of PMA on EPO production during 
a 72-h incubation was associated with a marked reduction 
of EPO mRNA accumulation in response to hypoxia (Fig. 
3, left). At the same time PMA treatment did not alter the 
production of angiotensinogen at 1% 0s (Fig. 3, right). 
After 72 h of incubation, PMA also led to an increase of 
cell mass at 20% (mean protein with 100 nM PMA: 36.2 
+ 2.2 pg/cm2; without PMA: 31.8 + 1.3 pg/cm2, n = 6) (P 
< 0.05) and to a slight decrease of cell mass at 1% oxygen 
(mean protein with 100 nM PMA: 26.7 + 1.4 Fg/cm2, n. = 
6; without PMA: 28.6 + 1.4 pg/cm2, n = 6) (P < 0.05). 
The effect of PMA (100 nM) on the translocation of 
(mean i SEM. n-5) 
Fig. 3. Left: audiograph of an RNase protection assay showing the accu- 
mulation of EPO mRNA in Hep G2 cells stimulated by a 72-h exposure 
to 1% O2 in the absence and presence of 100 nM PMA. Size of protected 
fragments (arrow) was -150 bp, corresponding to size of cDNA frag- 
ment used for generation of riboprobes. Right: mean cellular protein, 
EPO production, and angiotensinogen production for the cultures used 
for EPO mRNA determination as shown on left. Data are means + SE 
of 5 75-cm2 flasks each containing 15 ml of culture medium. 
the PKC isoenzymes CX, p, and y in Hep G2 was then 
examined. Among these isoenzymes the a-subtype was 
predominant, while P- and y-subtypes were expressed at 
low levels only. 
Treatment of the cells with PMA for 1 h led to a 
marked translocation of the a-subtype from the cytosol to 
the membrane (Fig. 4). After 24 h of incubation, when the 
inhibitory effect of PMA on EPO formation was fully 
expressed, immunoreactive cu-PKC was found in the cyto- 
sol only but not longer in the membranes (Fig. 4). Similar 
temporal patterns were seen with the /3- and y-isoen- 
zymes of PKC. To test for the specificity of the effects 
seen with PMA, the effects of other phorbol esters and of 
synthetic diacylglycerols were examined (Fig. 5). Phorbol 
12,13-dibutyrate (PDB) mimicked the effect of PMA, 
however, with marked less potency (ED,, = 1 PM), while 
4-a-phorbol12,13-didecanoate (4ol-PDD) was ineffective. 
The synthetic diacylglycerols 1-oleolyl-2-acetylglycerol 
and 1,2-dioctanoylglycerol had no effect either on basal 
(not shown) or stimulated EPO production (Fig. 5). 
Inhibition of EPO formation by PMA occurred rather 
rapidly and was apparent on the level of EPO mRNA 
already after 1 h of incubation (Fig. 6, lane 7 vs. lane 2 and 
lane 3 vs. lane 5) reached its maximum after 24 h and held 
on during the following 48 h (Fig. 6, lane 8 vs. lane 2 and 
lane 4 vs. lane 6: Fig. 7, bottom). For comparison, cell 
proliferation, as a more general parameter for protein 
synthesis, was only slightly attenuated during PMA 
treatment (Fig. 7, top). When the cells were preincubated 
with PMA for 24 h before exposure to hypoxia, EPO 
formation was virtually abolished by PMA treatment 
(Fig. 7, bottom). Under the same condition cell growth 
was slowed down but not blunted (Fig 7, top). To deter- 
mine the duration of the PMA effect on EPO formation, 
Hep G2 cells were preincubated with 100 nM PMA for 24 
h and then exposed to either 20% or 1% O2 in the absence 
of PMA. As shown in Fig. 8, a single day of preincubation 
with PMA was sufficient to markedly attenuate EPO 
formation during the next days. Two days after removal 
of PMA, EPO formation recovered and reached control 
values l-2 days later. It should be noted that a 24-h 
1 2 3 4 5 6 
Fig. 4. Autoradiograph of an immunoblot analysis of the ol-isoenzyme of 
protein kinase C (PKC) in cytosolic and membrane fractions of cultured 
Hep G2 cells. Arrow indicates PKC-(U immunoreactivity. Subconfluent 
cultures were incubated with 100 nM PMA for 0, 1, and 24 h. Lanes I, 
3, and 5 represent cytosolic fractions after 0, 1, and 24 h of incubation 
with PMA, respectively. Lanes 2,4, and 6 represent membrane fractions 
after 0, 1, and 24 h of incubation with PMA, respectively. 
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Fig. 5. Dependency of 72-h EPO production by cultured Hep G2 cells at 
1% O2 or with 100 PM cobalt on the concentration of phorbol 12,13- 
dibutyrate (PDB), 4Lu-phorbol 12,12-didecanoate (o-PDD), l-oleolyl-2- 
acetylglycerol (OAG), and 1,2-dioctanoylglycerol (DOG). Data are 
means rt SE of 4 experiments each. 
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Fig. 6. Autoradiograph of an RNase protection assay showing the accu- 
mulation of EPO mRNA in Hep G2 cells under different conditions (all 
cultures incubated for 24 h). Lane 1: molecular weight markers (Hpa II 
digest of pBR 322 DNA, see also legend to Fig. 3); lane 2: 20% O2 for 24 
h; lone 3: 20% for 23 h + 1% Oe plus PMA (100 nM) for the last hour 
(23-24th h of incubation); lane 4: 1% O2 for 24 h in the continuous 
presence of PMA (100 nM); lane 5: 20% O2 for 23 h + 1% O2 for the last 
hour; lane 6: 1% O2 for 24 h; he 7: 20% O2 for 24 h, PMA (100 nM) 
added for the last hour; lane 8: 20% 0, for 24 h in the continuous 
presence of 100 nM PMA. 
preincubation with PMA (100 nM) only did not signifi- 
cantly alter cell mass. 
A different approach to interfere with PKC activity is 
to use inhibitors of PKC. Two structurally different PKC 
inhibitors, namely staurosporine and H-7, were used, and 
they were found to also inhibit basal and stimulated EPO 
production in a concentration-dependent manner, with 
EDS0 values of - 10 nM and 50 PM, respectively (Fig. 9). 
Moreover, the PKC inhibitors further enhanced the 
inhibitory effects of PMA on EPO formation (Fig. 10). 
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Fig. 7. Temporal accumulation of cell protein (top) and EPO in the 
culture medium (bottom) of Hep G2 cells incubated at 1% O2 in the 
absence and in the presence of 100 nM PMA. Data are means + SE of 
quadruplicates under each condition. 
Combination of PMA (100 nM) and staurosporine (30 
nM) was sufficient to virtually blunt the stimulation of 
EPO production in response to low oxygen tension. Cell 
proliferation at 20% oxygen was not altered by either 
staurosporine or by H-7. At 1% oxygen, mean cell mass 
was reduced in presence of PKC inhibitors (mean protein 
control: 30.0 f 1.2 hg/cm2; staurosporine (100 nM): 26.4 
+ 1.0 Hg/cm2; H-7 (100 PM): 27.0 + 0.9 I.cg/cm2; n = 3 for 
each condition) (P < 0.05). 
DISCUSSION 
Our findings show and thus confirm previous results 
that EPO production in Hep G2 cells is stimulated by low 
oxygen tension and by cobalt (13, 19, 26). Moreover, the 
ability of EPO formation to be stimulated that was seen 
in this study was markedly greater when compared with 
previous studies. In our experience, this greater stimula- 
tion was the result of regular passaging, avoiding of cell 
clumping, 3-day incubation, and seeding of the cells at 
rather low density, a phenomenon that has already been 
recognized by others (13, 19, 26). 
The results obtained in this study suggest that PKC 
can exert influence on the regulation of EPO production 
in Hep G2 cells. Thus only active phorbol esters such as 
PMA and PDB inhibited EPO production in a concen- 
tration range typical for interference with PKC (Figs. 2 
and 5). Furthermore, two structurally different inhibitors 
of PKC activity also inhibited EPO production with 
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Fig. 8. Effect of a 24-h preincubation with 100 nM PMA on daily 
production rates of EPO by cultured Hep GZ cells. EPO production was 
stimulated by exposure to low oxygen tension (1% 0,). Data are means 
k SE of quadruplicates. 
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Fig. 9. Dependency of 72-h EPO production by cultured Hep G2 cells at 
20% and 1% O2 on the concentration of staurosporine A and l-(5- 
isoquinolinylsulfonyl) -2-methylpiperazine (H-7). Data are means t SE 
of 3 experiments each. 
EDS0 values compatible with preferential inhibition of 
PKC (Fig. 9). At first sight, the results obtained seem to 
be hardly compatible. Thus active phorbol esters known 
as potent activators of protein kinase C exerted profound 
effects on EPO formation during 72 h (Fig. 2), while 
synthetic diacylglycerols had no effect (Fig. 5). In addi- 
tion, inhibitors of PKC had the same effect as phorbol 
esters, and, moreover, they amplified the effects of phor- 
bol esters (Figs. 9 and 10). 
However, it is not unlikely that these seemingly diver- 
gent findings really fit together, because recent evidence 
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Fig. 10. EPO production (72 h) by cultured Hep G2 cells at 20% and 1% 
O2 in the combined presence of PMA and staurosporine (30 nM) or 
PMA and H-7 (50 PM). Data are means t SE of 3 experiments each. 
indicates that active phorbol esters have a dual effect on 
PKC, namely a rapid activation that is followed by deple- 
tion of PKC from cells due to the strong binding to phor- 
bol esters followed by proteolytic degradation (2, 15, 20, 
23) 
In fact, our findings show that in the case of PKC-a! 
treatment of Hep G2 cells with PMA causes a significant 
translocation of this PKC isoenzyme from the cytosol to 
the membrane, while continuous treatment with PMA 
for 24 h causes a nearly total disappearance of membrane- 
bound PKC-a! (Fig. 4). 
A somewhat surprising finding in this context was that 
there existed still a substantial amount of PKC-cu in the 
cytosol even after 24 h of incubation with 100 nM PMA. 
This observation, however, is in good accordance with a 
recent study demonstrating a comparably slow depletion 
of cytosolic PKC by 100 nM PMA in Hep G2 cells (8). 
Because membrane-bound PKC is known to be enzymat- 
ically degraded, the existence of cytosolic PKC in the 
continuous presence of PMA may indicate that the phor- 
bol ester could also stimulate de novo synthesis of the 
cu-isoenzyme. Nonetheless, the disappearance of mem- 
brane-bound PKC isoenzymes such as the a-subtype in 
the continuous presence of PMA suggests the depletion of 
active wPKC, because this isoenzyme is considered to be 
active in the membrane-bound state only. 
Our findings also show that a decrease of EPO mRNA 
in Hep G2 cells becomes apparent already after 1 h of 
incubation with 100 nM PMA at a time when PKC-cu 
(and PKC-p and -7) is presumably still activated. After 
24 h of incubation with 100 nM PMA, both EPO mRNA 
levels and EPO protein production rates were maximally 
suppressed (Figs. 6 and 7), while membrane-bound PKC- 
cy (-p and -7) had disappeared (Fig. 4). 
In principle, two main explanations could account for 
these observations. First, activation of PKC by phorbol 
esters generates a substrate that is inhibitory for EPO 
production and that is active over at least 72 h. If this 
substrate is produced by PKC-a, -fi, or -7, it must be a 
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very stable one because these PKC isoenzymes display a 
typical downregulation of the membrane-bound forms. 
To date, seven isoenzymes of the PKC family have been 
identified (21). Their modes of activation, their substrate 
specificity, and their sensitivity toward phorbol esters 
have not yet been characterized in detail for all of these 
subspecies. But there is already evidence that these func- 
tional characteristics may vary among the PKC subspe- 
cies (21). Also, the temporal pattern of downregulation by 
prolonged exposure to phorbol ester has been found to be 
not only dependent on the PKC subspecies (15) but also 
on the cell type considered (1). We cannot rule out the 
possibility therefore that a certain PKC isoenzyme dif- 
ferent from PKC-(x, -p, or -y is continuously activated in 
Hep G2 cells in the presence of phorbol esters. With the 
same arguments, however, it could be speculated that it is 
the downregulation of a certain PKC isoenzyme probably 
different from PKC-cu, -0, or -7 that is responsible for the 
attentuation of EPO mRNA levels and EPO protein 
synthesis. Circumstantial evidence would in fact support 
this latter view. Thus synthetic diaglycerols which cause 
activation of PKC but do not cause downregulation of the 
isoenzymes (20) were without effect on EPO synthesis 
(Fig. 5). The effect of PMA on EPO production holds on 
~48 h after removal of the phorbol esters (Fig. 8). Inhib- 
itors of PKC activity do not inhibit the effects of active 
phorbol esters on EPO production but conversely them- 
selves attenuate EPO production (Fig. 9) and, moreover, 
amplify the inhibitory effects of phorbol esters (Fig. 10). 
If the concept that it is the downregulation rather than 
the activation of a certain PKC isoenzyme is true, the 
question about the nature of this isoenzyme is raised 
again. Considering the kinetics of activation and down- 
regulation of PKC-CX, -p, and -y by PMA, it is not very 
likely that the downregulation of these particular isoen- 
zymes is exclusively responsible for the attenuation of 
EPO production. A third possibility to explain the 
obtained findings is that it is the combination of activa- 
tion of certain PKC isoenzyme(s) and downregulation of 
certain PKC isoenzymes(s) that produce the inhibition of 
EPO synthesis. 
Regardless of the specific mechanism that has to be 
clarified in future experiments, the question arises 
whether this possible role of PKC is specific for EPO 
synthesis or reflects a more general cellular phenomenon. 
It has been noted in previous studies that phorbol ester 
treatment causes a transient slow down of cell prolifera- 
tion in Hep G2 (8). We observed a similar effect both at 
20 and 1% oxygen (Fig. 7). Growth retardation at 20% 
oxygen was only transient and after 72 h cell mass in 
presence of PMA was even slightly increased. Neverthe- 
less, the growth retardation under phorbol ester as seen in 
this study was small when compared with the inhibition 
of EPO synthesis and decrease of EPO mRNA 
accumulation. In consequence, one may infer that mRNA 
accumulation in Hep G2 cells is not generally inhibited 
after prolonged exposure to phorbol ester. This conclu- 
sion is supported by previous reports that in states of 
significantly downregulated PKC activity the expression 
of c-fos, transforming growth factor-p, albumin, cu-feto- 
protein, and c-myc is not altered in Hep G2 cells (8). Our 
measurements, moreover, show that prolonged exposure 
to phorbol esters also did not alter the synthesis rate of 
other proteins constitutively secreted by Hep G2 such as 
angiotensinogen which is produced in a cell cycle-related 
fashion (7). It appears, therefore, that the possible effect 
of PKC on the regulation of EPO formation is a more 
specific one and that the observed effects are not prima- 
rily due to nonspecific cell toxic effects of phorbol esters. 
It must be a task for future research to clearly identify 
the PKC species that appear(s) to be effective in the 
regulation of EPO production in Hep G2 cells. The gen- 
eral mechanisms regulating EPO mRNA accumulation in 
hepatoma cells are understood only in their very first 
beginnings. There is evidence that both the transcrip- 
tional activity of the EPO gene as well as the stability of 
EPO mRNA are subject to regulation, in a way that 
hypoxia enhances both EPO gene transcription and EPO 
mRNA stability (12, 13). Indirect evidence, moreover, 
suggests that a heme protein acting as a molecular oxygen 
sensor could be involved in the control of these processes 
(11). Therefore, PKC activity could interfere with EPO 
formation at several sites, at the heme protein, directly at 
the EPO gene, or at the stabilization of EPO mRNA. 
It could be of interest in this context that recently 
a bacterial heme protein functioning as a molecular 
oxygen sensor has been demonstrated to exert a kinase 
activity (10). 
l While this manuscript was under consideration, Jelkmann et al. 
provided evidence for a permissive role of PKC-cw in the regulation of 
EPO production in Hep G2 cells (Biochem. Biophys. Res. Commun. 179: 
1441-1448, 1991). 
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